readthroughSign in
Nov 13, 2026People

Abbott extends change-in-control agreements for executives, not CEO Ford

Abbott notified named executive officers on November 11, 2026 that their change-in-control agreements run through 2028, while CEO Robert Ford's agreement still expires at the end of 2026.

Abbott Laboratories disclosed in an 8-K filed for a November 11, 2026 event that it has extended the terms of Change in Control Agreements held by its named executive officers, with one exception.

Abbott maintains Agreements Regarding Change in Control with its named executive officers.1 Under the terms of those agreements, Abbott can extend the agreement's term through the second anniversary of the expiration date if it provides notice before that expiration date, which was set at December 31, 2026.1

Abbott exercised that option on November 11, 2026. The company informed its named executive officers, excluding Chairman and CEO Robert B. Ford, that their agreements would now run through December 31, 2028.1 Ford's own agreement was not extended and remains set to expire on December 31, 2026.1

The filing does not specify which other named executive officers are covered or detail the substantive terms of the change-in-control agreements beyond the extension itself. It was signed by Philip P. Boudreau, Abbott's Executive Vice President, Finance and Chief Financial Officer, and dated November 13, 2026.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.